Choroid plexus cysts (CPCs) are often transient and benign findings observed in pregnancy screenings. This study aimed to examine the association between the frequency of congenital heart diseases and the detection of CPCs. In this prospective case-control study, pregnant mothers with no predisposing risk factors for the development of fetal cardiac abnormalities were eligible for entry. Based on the presence or absence of CPCs on ultrasound, the enrolled fetuses were divided into two groups. All patients (n = 100) underwent two-dimensional and color Doppler echocardiography to identify potential cardiac anomalies. Overall, CPCs were detected in 53 enrolled fetuses, and the remainder were enrolled as controls (n = 47). Pathological findings, such as echogenic intracardiac focus (EIF), ductal spasm, atrial septal defect (ASD), pericardial effusion, cardiomyopathy, and congenital heart disease were found in neither group. In the CPC group, two mild and six trivial cases of tricuspid regurgitation (TR) were detected. In the controls, five cases of trivial TR were identified. In conclusion, the presence of CPCs was not associated with significant functional or structural fetal cardiac abnormalities, which may be due to altered developmental mechanisms.
Introduction: Given the importance of coronary artery disease and the range of cardiovascular disease phenotypes in smokers, as well as the potential genetic and epigenetic factors, we were motivated to explore the impact of smoking on some selected microRNAs associated with atherosclerosis. Methods: A total of 60 individuals were selected in four groups including non-smoker without atherosclerosis (S-A-), non-smokers with atherosclerosis (S-A+), smokers without atherosclerosis (S+A-) and smokers with atherosclerosis (S+A+). Micro-RNA expression was investigated using real-time PCR. General linear model was used to calculate fold change (FC) considering S-A- as the reference group. Results: For mir-34a, down-regulation was observed in S+A- (FC =0.13, P =0.007) and S+A+ (FC =0.23, P =0.036) groups. For mir-126-3p, down-regulation was observed in S-A+ group (FC =0.05, P =0.024). For mir-199, up-regulation was observed for S+A- group (FC =9.38, P =0.007). The only significant interaction between pack-years of smoking and number of atherosclerotic vessels was for mir-199 which was in favor of down-regulation (P =0.006), while the main effects were in favor of up-regulation (P <0.05). Conclusion:Mir-34a expression may be affected by smoking, whereas mir-126-3p expression may be affected by atherosclerosis. The significant down-regulation of mir-199 for the interaction of smoking dose and severity of atherosclerosis was a notable finding showing the harmful consequence of this interaction. Further studies are needed for this micro-RNA.
Background: Intrahepatic cholestasis of pregnancy (ICP) is associated with an increased risk of adverse perinatal outcomes. Simple prognostic biomarkers are needed for risk stratification. The Albumin-Bilirubin (ALBI) score and Aspartate Aminotransferase to Alanine Aminotransferase ratio (De Ritis) are established liver function indices, but their comparative utility for predicting adverse perinatal outcomes in ICP remains inadequately explored.This study aimed to evaluate and compare the prognostic performance of the ALBI score and the De Ritis ratio for predicting ICP and adverse perinatal outcomes.Methods: A retrospective study was conducted utilizing a publicly available dataset comprising 100 pregnant women with a diagnosis of ICP. The ALBI score and De Ritis ratio were calculated from serum biomarkers. Univariate and multivariable logistic regression were used to assess associations, presented as odds ratios (OR) with 95% confidence intervals (CI). Predictive performance was evaluated using Receiver Operating Characteristic (ROC) curve analysis, reporting the area under the curve (AUC), sensitivity, and specificity.Results: In univariate analysis, the ALBI score was a significant predictor of adverse outcomes (OR=20.54, p<0.001), while the De Ritis ratio was not (OR=0.78, p=0.42). The ALBI score demonstrated significantly superior discriminatory power (AUC=0.712). In multivariable models adjusting for gestational age, maternal age, ALP, and GGT, the ALBI score remained a strong, independent predictor (fully adjusted OR=21.65, p=0.006), whereas the De Ritis ratio was consistently non-significant. A model combining both scores showed good predictive performance (AUC=0.714), which was significantly enhanced to an excellent level (AUC=0.845) after full adjustment for clinical covariates.Conclusion: The ALBI score is a significant and independent predictor of ICP and adverse perinatal outcomes in the pregnancy, demonstrating good prognostic utility. In contrast, the De Ritis ratio showed no meaningful predictive value. The ALBI score could serve as a useful clinical tool for risk assessment in this patient population.
Background: Acute heart failure (AHF) is a significant cardiovascular syndrome characterized by either new-onset heart failure (HF) or acutely decompensated heart failure (ADHF), typically presenting with systemic and pulmonary congestion. The European Society of Cardiology has reinforced the importance of early guideline-directed medical therapy (GDMT) initiation and individualized decongestive strategies. This article explores current knowledge of AHF pathophysiology. The simplified hemodynamic paradigm previously used to explain AHF has been replaced over the past few decades by a more complex network of interacting mechanisms. Main text: The clinical presentation of AHF reflects a heterogeneous combination of cardiac abnormalities and systemic pathophysiological processes rather than a single disease entity. Despite overlapping clinical presentations, AHF arises from diverse underlying conditions and pathophysiological mechanisms. Left ventricular systolic or diastolic dysfunction elevates filling pressures, contributing to increased preload and afterload, which in turn promotes pulmonary congestion. End-organ dysfunction may result from the combined effects of venous congestion, impaired perfusion, and neurohormonal and inflammatory activation. Despite advances, limited progress in acute management may contribute to persistently poor outcomes in AHF patients. Conclusion: Initial management of AHF commonly includes intravenous diuretics for patients with congestion, while vasodilators and other therapies are selected according to congestion status, perfusion, blood pressure, hemodynamic profile, clinical phenotype, and the predominant underlying pathophysiological mechanism. This review examines pathophysiological processes contributing to AHF onset and progression, highlighting clinical implications and therapeutic targets.